Evome Medical Technologies Bolsters Board of Directors With Appointment of Strategic Senior Healthcare Executives Wayne Anderson and Bill Garbarini, Appoints Kenneth Kashkin, MD, as Chairman
Evome Medical Technologies Bolsters Board of Directors With Appointment of Strategic Senior Healthcare Executives Wayne Anderson and Bill Garbarini, Appoints Kenneth Kashkin, MD, as Chairman
NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the "Company" or "Evome") announces the appointment of two senior healthcare executives to its Board of Directors.
紐約，2024年2月15日（GLOBE NEWSWIRE）——Evome Medical Technologies Inc.（“公司” 或 “Evome”）宣佈任命兩名高級醫療保健高管爲董事會成員。
Mr. Wayne Anderson, former President and CEO of Ferring Pharmaceuticals USA, has joined as a non-executive member of the Board of Directors.
美國輝凌製藥公司前總裁兼首席執行官韋恩·安德森先生已加入董事會member 擔任非執行董事。
Mr. Bill Garbarini, a former Ferring Pharmaceuticals USA executive and current COO of Conceivable Life Sciences, a venture backed in-vitro fertilization company, will also join as a non-executive member of the Board of Directors.
美國輝凌製藥公司前高管、風險投資支持的體外受精公司Conceivable Life Sciences的現任首席運營官比爾·加巴里尼先生也將加入董事會擔任非執行成員。
In addition, Kenneth Kashkin, MD, has been appointed Chairman of the Board of Directors. Dr. Kashkin is Board Certified in Internal Medicine, Neurology & Psychiatry with training at, and serving on, the faculties of the University of California, Los Angeles (UCLA) and Yale University Schools of Medicine. He has led development at divisions of Bayer, Abbott, Knoll/BASF Pharma and Baxter.
此外，醫學博士肯尼思·卡什金被任命爲董事會主席。卡什金博士獲得內科、神經病學和精神病學委員會認證，曾在加州大學洛杉磯分校（UCLA）和耶魯大學醫學院接受過培訓和任職。他曾領導拜耳、雅培、諾爾/巴斯夫製藥和百特等部門的開發。
"Now that we have successfully executed on our turnaround plan, I am pleased to have Wayne and Bill join the Board," said Mike Seckler, CEO of Evome. "I worked with both of these talented and successful healthcare executives for many years while at Ferring and I am eager to benefit from their valuable guidance and expertise, particularly in the realms of product launch and commercialization. Dr. Kashkin's contributions will play a crucial role in advancing our innovation and development strategies, aligning with our vision to democratize our Biodex Brands. I can now say we have completed all of the necessary steps to transform our company. We have driven revenue growth, developed new products, cut costs and restructured our debt. The final step was to add some seasoned talent to our Board to assist us in driving shareholder value."
Evome首席執行官邁克·塞克勒說：“現在我們已經成功執行了週轉計劃，我很高興韋恩和比爾加入Board。”“在輝凌工作期間，我與這兩位才華橫溢且成功的醫療保健高管合作了多年，我渴望從他們在產品發佈和商業化領域的寶貴指導和專業知識中受益particularly。卡什金博士的貢獻將在推進我們的創新和發展戰略方面發揮至關重要的作用，這符合我們實現Biodex 品牌大衆化的願景。我現在可以說我們已經完成了公司轉型的所有必要步驟。我們have 推動了收入增長，開發了新產品，削減了成本並重組了債務。最後一步是to 爲我們的董事會增加一些經驗豐富的人才，以幫助我們提高股東價值。”
For more information please contact:
欲了解更多信息，請聯繫：
Mike Seckler
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: info@evomemedical.com
邁克·塞克勒
首席執行官
電話：1 (800) 760-6826
電子郵件：info@evomemedical.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險交易所及其監管服務提供商（該術語在the 多倫多證券交易所風險投資交易所的policies 中定義）均不對本release 的充分性或準確性承擔責任。
譯文內容由第三人軟體翻譯。